Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Urogen Pharma Ltd (URGN)

Urogen Pharma Ltd (URGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Why Shares of UroGen Pharma Jumped Friday Motley Fool - Fri Jul 28, 2023

The company released positive top-line results for two studies for a bladder cancer treatment.

URGN : 14.19 (-0.35%)
Urogen Pharma (URGN) Reports Q1 Loss, Tops Revenue Estimates Zacks - Thu May 11, 2023

Urogen Pharma (URGN) delivered earnings and revenue surprises of 6.47% and 3.88%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

URGN : 14.19 (-0.35%)
LFCR : 6.28 (-3.83%)
Adicet Bio, Inc. (ACET) Reports Q1 Loss, Misses Revenue Estimates Zacks - Tue May 9, 2023

Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of 2.70% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ACET : 2.04 (-10.13%)
URGN : 14.19 (-0.35%)
UroGen Pharma to Report 2023 First Quarter Financial Results on Thursday, May 11, 2023 Business Wire - Thu May 4, 2023

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report 2023...

URGN : 14.19 (-0.35%)
Earnings Preview: Urogen Pharma (URGN) Q1 Earnings Expected to Decline Zacks - Tue May 2, 2023

Urogen Pharma (URGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

URGN : 14.19 (-0.35%)
CYTK : 67.02 (-1.34%)
First Study to Evaluate JELMYTO® Use Post-Complete Endoscopic Ablation Reports 69% of Patients were Disease Free at the Time of First Endoscopic Evaluation Business Wire - Mon May 1, 2023

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis...

URGN : 14.19 (-0.35%)
New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal Pelvis Business Wire - Sun Apr 30, 2023

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis...

URGN : 14.19 (-0.35%)
UroGen Pharma to Present at H.C. Wainwright BioConnect Conference Business Wire - Tue Apr 25, 2023

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate...

URGN : 14.19 (-0.35%)
Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates Zacks - Thu Mar 16, 2023

Urogen Pharma (URGN) delivered earnings and revenue surprises of -8.93% and 0.87%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

URGN : 14.19 (-0.35%)
HUMA : 3.59 (+15.06%)
UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments Business Wire - Thu Mar 16, 2023

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for...

URGN : 14.19 (-0.35%)

Barchart Exclusives

1 Semiconductor Stock Set to Benefit from Meta's New AI Chip Barchart - 18 minutes ago
TSM's collaboration with Meta in fabricating new AI chips positions its shares for continued upside. Let’s take a closer look. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot